DURHAM, N.C. (
said Thursday its experimental drug Prolacria for dry eye disease failed to meet the primary or secondary goals of a phase III study.
"We have provided the top-line results from this trial to our partner
and we will be conducting a thorough review of the program before determining next steps, if any," said Inspire CEO Christy Shaffer, in a statement.
The U.S. Food and Drug Administration has twice turned down Inspire's previous efforts at getting Prolacria approved.
Inspire shares closed Wednesday at $6.61.
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.